Literature DB >> 7806917

Multiple field hyperthermia combined with radiotherapy in advanced carcinoma of the breast.

K Engin1, L Tupchong, F M Waterman, L Komarnicky, C M Mansfield, N Hussain, L L Hoh, J D McFarlane, D B Leeper.   

Abstract

Extensive recurrences on the chest wall of advanced carcinoma of the breast in 20 patients were treated with multiple field patchwork hyperthermia combined with radiation therapy between 1987-1991. The objective of the study was to evaluate the feasibility, tumour response and complications of treating extensive lesions with multiple, overlapping fields of hyperthermia. All lesions were diffuse encompassing up to 2900 cm2 in area with or without multiple nodules < or = 3 cm deep. All lesions had failed previous therapy with all but three failing previous radiotherapy. Hyperthermia consisted of 282 hyperthermia applicator fields and 357 hyperthermia treatments with external 915 MHz microwaves using commercially available applicators. Hyperthermia applicator fields were defined by the surface 50% SAR distribution of a particular applicator, and hyperthermia fields were abutted to cover the entire tumour bearing area. Radiation therapy consisted of 81 fields to a mean dose of 40 +/- 1 Gy (SE), 88% of fields received between 30 and 50 Gy. The equivalent dose was 42 +/- 1 Gy, based on the linear-quadratic model and alpha/beta = 25 (Fowler 1989). Overlapping hyperthermia fields were separated by an interval of at least three days. Up to four heat sessions per week were required to cover the entire tumour in a rotating fashion. The hyperthermia treatment time was 60 min. Hyperthermia treatments were continued for the duration of radiation therapy. Each hyperthermia applicator field was heated at least once. Patients were exposed to a mean of 14 +/- 3 hyperthermia applicator fields (range of 3-46 fields) and a mean of 18 +/- 3 hyperthermia treatments (range of 6-61) delivered over a mean of 7.5 +/- 0.9 weeks (range of 3-17 weeks). Each field was heated an average of 1.3 times. The tumour complete response rate was 95% with a recurrence rate of 5%. Nevertheless, the mean survival of patients with a complete response was only 10.8 +/- 1.7 months (range of 2-28 months) because of the systemic tumour burden existing outside of the treated fields in these patients. Neither complete response, local control nor survival after thermoradiotherapy correlated with the disease free interval between initial mastectomy and recurrence. There was no evidence of increased thermal damage to skin nor evidence of tumour recurrence at junctions of hyperthermia field overlap. It is concluded that recurrent advanced carcinoma of the breast presenting as extensive, diffuse lesions on the chest wall can be treated as effectively with multiple field patchwork thermoradiotherapy as can nodular lesions treated with single hyperthermia fields.

Entities:  

Mesh:

Year:  1994        PMID: 7806917     DOI: 10.3109/02656739409022440

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  3 in total

1.  Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy.

Authors:  Timothy M Zagar; Kristin A Higgins; Edward F Miles; Zeljko Vujaskovic; Mark W Dewhirst; Robert W Clough; Leonard R Prosnitz; Ellen L Jones
Journal:  Radiother Oncol       Date:  2010-11-11       Impact factor: 6.280

2.  Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data.

Authors:  Vassilis Kouloulias; Sotiria Triantopoulou; Nikolaos Uzunoglou; Kyriaki Pistevou-Gompaki; Alfred Barich; Anna Zygogianni; George Kyrgias; Dimitris Kardamakis; Dimitris Pectasidis; John Kouvaris
Journal:  Breast Care (Basel)       Date:  2015-04       Impact factor: 2.860

3.  Characterization of mild whole-body hyperthermia protocols using human breast, ovarian, and colon tumors grown in severe combined immunodeficient mice.

Authors:  E A Repasky; E Tims; M Pritchard; R Burd
Journal:  Infect Dis Obstet Gynecol       Date:  1999
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.